621 / 1241
Significant survival advantage for the patients with recurrent
gliomas treated with SFR based on AS-PET/SPECT/MRI/CT
(median 9 mo,mean 14 mo)
compared to the patients treated
with SFR planned by anatomical imaging (CT/MRI)
(median 5
mo, mean 6 mo), p = 0.031
(Grosu IJROBP 2005)
Months
50
40
30
20
10
0
Survival (%)
1,2
1,0
,8
,6
,4
,2
0,0
PET or SPECT
no
yes
Survival curves for patients with recurrent gliomas treated with SFR based on
biological imaging and temozolomide
(median 11 months, mean 16 months)
vs. patients treated with SFR without temozolomide, without biological imaging
or without both components
(median 6 months, mean 8 months), p=0.008
(Grosu IJROBP 2005)
Months
50
40
30
20
10
0
Survival (%)
1,2
1,0
,8
,6
,4
,2
0,0
PET/SPECT+Temoz
yes
no
Re-irradiation of recurrent high grade gliomas.
SFR, 30 Gy, 5Gy/f +TMZ : AA-PET/CT/MRI plan vs. CT/MRI plan